Cogent Stock Based Compensation from 2010 to 2025

COGT Stock  USD 6.48  0.13  1.97%   
Cogent Biosciences Stock Based Compensation yearly trend continues to be comparatively stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals
 
Stock Based Compensation  
First Reported
2017-03-31
Previous Quarter
10.4 M
Current Value
10 M
Quarterly Volatility
3.5 M
 
Covid
Check Cogent Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cogent Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 4.8 M or Selling General Administrative of 45.4 M, as well as many indicators such as Price To Sales Ratio of 35.83, Dividend Yield of 0.0 or PTB Ratio of 3.48. Cogent financial statements analysis is a perfect complement when working with Cogent Biosciences Valuation or Volatility modules.
  
Check out the analysis of Cogent Biosciences Correlation against competitors.
For more information on how to buy Cogent Stock please use our How to Invest in Cogent Biosciences guide.

Latest Cogent Biosciences' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Cogent Biosciences over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Cogent Biosciences' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cogent Biosciences' overall financial position and show how it may be relating to other accounts over time.
Stock Based Compensation10 Years Trend
Slightly volatile
   Stock Based Compensation   
       Timeline  

Cogent Stock Based Compensation Regression Statistics

Arithmetic Mean9,895,812
Geometric Mean2,149,736
Coefficient Of Variation148.16
Mean Deviation11,582,867
Median3,088,000
Standard Deviation14,661,996
Sample Variance215T
Range41.5M
R-Value0.84
Mean Square Error69.5T
R-Squared0.70
Significance0.000055
Slope2,573,672
Total Sum of Squares3224.6T

Cogent Stock Based Compensation History

202541.7 M
202439.7 M
202330.6 M
202218.4 M
202111.7 M
2020M
20193.2 M

Other Fundumenentals of Cogent Biosciences

Cogent Biosciences Stock Based Compensation component correlations

0.990.52-0.57-0.830.730.710.741.00.350.820.930.980.920.99-0.280.87
0.990.46-0.65-0.790.680.650.661.00.420.790.930.990.940.97-0.360.82
0.520.460.07-0.830.850.830.720.5-0.020.810.50.470.450.56-0.120.65
-0.57-0.650.070.24-0.040.090.09-0.62-0.8-0.25-0.56-0.68-0.77-0.480.77-0.14
-0.83-0.79-0.830.24-0.97-0.9-0.82-0.81-0.11-0.99-0.79-0.8-0.77-0.880.23-0.89
0.730.680.85-0.04-0.970.950.840.7-0.070.970.710.680.610.8-0.110.88
0.710.650.830.09-0.90.950.890.67-0.20.90.650.630.520.770.10.88
0.740.660.720.09-0.820.840.890.7-0.190.80.620.630.530.80.260.94
1.01.00.5-0.62-0.810.70.670.70.390.810.920.990.940.98-0.330.84
0.350.42-0.02-0.8-0.11-0.07-0.2-0.190.390.160.510.480.510.29-0.660.02
0.820.790.81-0.25-0.990.970.90.80.810.160.830.80.750.87-0.230.89
0.930.930.5-0.56-0.790.710.650.620.920.510.830.940.850.92-0.320.79
0.980.990.47-0.68-0.80.680.630.630.990.480.80.940.960.96-0.40.8
0.920.940.45-0.77-0.770.610.520.530.940.510.750.850.960.89-0.530.69
0.990.970.56-0.48-0.880.80.770.80.980.290.870.920.960.89-0.230.93
-0.28-0.36-0.120.770.23-0.110.10.26-0.33-0.66-0.23-0.32-0.4-0.53-0.230.04
0.870.820.65-0.14-0.890.880.880.940.840.020.890.790.80.690.930.04
Click cells to compare fundamentals

About Cogent Biosciences Financial Statements

Cogent Biosciences shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Cogent Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Cogent Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Cogent Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Stock Based Compensation39.7 M41.7 M
Stock Based Compensation To Revenue 0.69  0.72 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cogent Stock Analysis

When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.